FDA considers adding a dozen peptides to its bulk drug compounding list RAPS FDA mulls compounding for peptides previously flagged over safety risks BioSpace The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what BPC 157 FDA Approval Status 2026: RFK Jr, Advisory Committee & Reclassification